MetaCap

Septerna Inc. (SEPN)

NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

38.61-0.59 (-1.51%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SEPN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.30
52-week range
22.78 – 53.34
Day range
38.23 – 39.89
Volume / Avg
374.25K / 383.96K
Beta
—

52-week range

$22.78$53.34

SEPN stock today

Septerna (SEPN) closed at $38.61 on Nov 20, down 1.51% (-$0.59), versus the S&P 500's 3.70% decline. At this level, SEPN sits in the middle of its 52-week range of $22.78 to $53.34: 27.6% below the high, set on Nov 11, 2026 and 69.5% above the low. SEPN is up 38.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.1%.

Septerna has posted a net loss over the last twelve months (EPS of -$1.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Septerna

Company profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jeffrey T. Finer M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
134
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Septerna generated $46.0 million in revenue, up 4174.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Septerna reported a net loss of $48.9 million, compared with a loss of $71.8 million a year earlier. Operating margin was -148.6%.

Septerna annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$45.95M$1.07M$151.00K
Growth+4174.51%+611.92%—
Net income$-48.88M$-71.80M$4.18M
EPS (diluted)$-1.10$-7.26$0.29

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$59.22+53.38%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $48.00High $65.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.57 vs $-0.55
Surprise
-3.64%

SEPN news

All SEPN news

Septerna peers

Health Care sector
SEPN peer companies
CompanyPrice% ChgMarket capCompare
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs SEPN
IMNMImmunome Inc.15.69-5.54%$1.85Bvs SEPN
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs SEPN
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs SEPN
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs SEPN
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs SEPN
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs SEPN
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs SEPN

Indexes, lists and sector

Septerna stock FAQ

What is Septerna's stock price today?

SEPN last traded at $38.61 as of Nov 20, 4:00 PM EST, down 1.51% on the day. Prices are delayed at least 15 minutes.

Who is Septerna's CEO?

Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna Inc., which has about 134 employees.

What is the SEPN 52-week high?

The 52-week high for SEPN is $53.34 and the 52-week low is $22.78. The stock is currently 27.6% below its high.

Compare SEPN